Background: Although the ability of basophils to release mediators, called releasability, may be an important aspect which influences the proinflammatory role of these cells, clinical approaches aiming at the depletion of the releasability have not been established. We examined whether the desensitization procedure in Ca2+-containing physiological conditions can make basophils completely unresponsive to IgE-mediated stimulation, and whether basophil desensitization is affected by the surface IgE levels. Methods: Human peripheral blood basophils were cultured with low concentrations of anti-IgE antibody or recombinant mite allergen. Following culture, cells were stimulated and their histamine release was measured. Results: Culturing with mite allergen or anti-IgE antibody below threshold concentrations induced potent desensitization in basophils. The desensitizing effect of anti-IgE was dose- and time-dependent; IgE-dependent releasability was completely suppressed when basophils were incubated with a near-threshold concentration of anti-IgE for ≧4 h. In the continuous presence of subthreshold doses of anti-IgE, basophils remained desensitized even after 3 days. Basophils which had undergone an increase in surface IgE levels after 24-hour culture with IgE demonstrated enhanced desensitization. Conclusions: Near-threshold stimulation in physiological medium can affect basophils, thereby inducing complete and sustained deprivation of releasability without triggering degranulation. Basophil desensitization is regulated by their surface IgE levels. Induction of full desensitization may represent a potentially important therapeutic strategy for IgE-mediated allergic diseases in which basophils play pathogenic roles.

Keywords:
Basophils, IgE, Anti-IgE antibody, Histamine release, Desensitization, FcεRI, Mite
1.
Ishizaka T, Ishizaka K: Activation of mast cells for mediator release through IgE receptors. Prog Allergy 1984;34:188–235.
2.
Costa JJ, Weller PF, Galli SJ: The cells of the allergic response: Mast cells, basophils, and eosinophils. JAMA 1997;278:1815–1822.
3.
Kinet JP: The high-affinity IgE receptor (FcεRI): From physiology to pathology. Annu Rev Immunol 1999;17:931–972.
4.
Dombrowicz D, Flamand V, Brigman KK, Koller BH, Kinet J-P: Abolition of anaphylaxis by targeted disruption of the high affinity immunoglobulin E receptor α chain gene. Cell 1993;75:969–976.
5.
Yamaguchi M, Lantz CS, Oettgen HC, Katona IM, Fleming T, Miyajima I, Kinet J-P, Galli SJ: IgE enhances mouse mast cell FcεRI expression in vitro and in vivo: Evidence for a novel amplification mechanism in IgE-dependent reactions. J Exp Med 1997;185:663–672.
6.
MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM: Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438–1445.
7.
Lantz CS, Yamaguchi M, Oettgen HC, Katona IM, Miyajima I, Kinet J-P, Galli SJ: IgE regulates mouse basophil FcεRI expression in vivo. J Immunol 1997;158:2517–2521.
8.
Yamaguchi M, Sayama K, Yano K, Lantz CS, Noben-Trauth N, Ra C, Costa JJ, Galli SJ: IgE enhances FcεRI expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: Synergistic effect of IL-4 and IgE on human mast cell FcεRI expression and mediator release. J Immunol 1999;162:5455–5465.
9.
MacGlashan D Jr, Schroeder JT: Functional consequences of FcεRIα up-regulation by IgE in human basophils. J Leukoc Biol 2000;68:479–486.
10.
Lichtenstein LM, MacGlashan DW Jr: The concept of basophil releasability. J Allergy Clin Immunol 1986;77:291–294.
11.
MacGlashan DW Jr: Releasability of human basophils: Cellular sensitivity and maximal histamine release are independent variables. J Allergy Clin Immunol 1993;91:605–615.
12.
Marone G, Spadaro G, Patella V, Genovese A: The clinical relevance of basophil releasability. J Allergy Clin Immunol 1994;94:1293–1303.
13.
Lichtenstein LM, Osler AG: Studies on the mechanisms of hypersensitivity phenomena. IX. Histamine release from human leukocytes by ragweed pollen antigen. J Exp Med 1964;120:507–530.
14.
MacGlashan D Jr, Lavens-Phillips S, Miura K: IgE-mediated desensitization in human basophils and mast cells. Front Biosci 1998;3:D746–D756.
15.
Pruzansky JJ, Patterson R: Desensitization of human basophils with suboptimal concentrations of agonist. Evidence for reversible and irreversible desensitization. Immunology 1988;65:443–447.
16.
Mendoza GR, Minagawa K: Subthreshold and suboptimal desensitization of human basophils. II. Nonspecificity and irreversibility of desensitization. Int Arch Allergy Appl Immunol 1982;69:282–284.
17.
Mendoza GR, Minagawa K: Subthreshold and suboptimal desensitization human basophils. I. Kinetics of decay of releasability. Int Arch Allergy Appl Immunol 1982;68:101–107.
18.
Yuuki T, Okumura Y, Ando T, Yamakawa H, Suko M, Haida M, Okudaira H: Cloning and expression of cDNA coding for the major house dust mite allergen Der f II in Escherichia coli. Agric Biol Chem 1991;55:1233–1238.
19.
Guidelines for the Diagnosis and Management of Asthma. Expert Panel Report II. Bethesda, National Institute of Health, 1997, NIH publication No 97-4051.
20.
Hirai K, Morita Y, Misaki Y, Ohta K, Takaishi T, Suzuki S, Motoyoshi K, Miyamoto T: Modulation of human basophil histamine release by hemopoietic growth factors. J Immunol 1988;141:3958–3964.
21.
Sobotka AK, Dembo M, Goldstein B, Lichtenstein LM: Antigen-specific desensitization of human basophils. J Immunol 1979;122:511–517.
22.
MacGlashan DW Jr, Lichtenstein LM: The transition from specific to nonspecific desensitization in human basophils. J Immunol 1981;127:2410–2414.
23.
Lichtenstein LM: The mechanism of basophil histamine release induced by antigen and by the calcium ionophore A23187. J Immunol 1975;114:1692–1699.
24.
Goldstein B, Dembo M, Sobotka AK, Lichtenstein LM: Some invariant properties of IgE-mediated basophil activation and desensitization. J Immunol 1979;123:1873–1882.
25.
MacGlashan D Jr, Mogowski M, Lichtenstein LM: Studies of antigen binding on human basophils. II. Continued expression of antigen-specific IgE during antigen-induced desensitization. J Immunol 1983;130:2337–2342.
26.
Marone G, Poto S, Celestino D, Bonini S: Human basophil releasability. III. Genetic control of human basophil releasability. J Immunol 1986;137:3588–3592.
27.
Gaddy JN, Busse WW: Enhanced IgE-dependent basophil histamine release and airway reactivity in asthma. Am Rev Respir Dis 1986;134:969–974.
28.
Casolaro V, Spadaro G, Marone G: Human basophil releasability. VI. Changes in basophil releasability in patients with allergic rhinitis or bronchial asthma. Am Rev Respir Dis 1990;142:1108–1111.
29.
Bischoff SC, Zwahlen R, Stucki M, Mullner G, de Weck AL, Stadler BM, Dahinden CA: Basophil histamine release and leukotriene production in response to anti-IgE and anti-IgE receptor antibodies. Comparison of normal subjects and patients with urticaria, atopic dermatitis or bronchial asthma. Int Arch Allergy Immunol 1996;110:261–271.
30.
Hirai K, Miyamasu M, Takaishi T, Morita Y: Regulation of the function of eosinophils and basophils. Crit Rev Immunol 1997;17:325–352.
31.
Ishizaka T, Sterk AR, Daëron M, Becker EL, Ishizaka K: Biochemical analysis of desensitization of mouse mast cells. J Immunol 1985;135:492–501.
32.
MacGlashan D Jr, Lichtenstein LM: Basic characteristics of human lung mast cell desensitization. J Immunol 1987;139:501–505.
33.
MacGlashan D Jr, Miura K, Lavens-Phillips S: Pharmacology of IgE-mediated desensitization of human basophils: Effects of protein kinase C and src-family kinase inhibitors. Biochem Pharmacol 2000;60:1717–1727.
34.
Yamaguchi M, Hirai K, Komiya A, Miyamasu M, Furumoto Y, Teshima R, Ohta K, Morita Y, Galli SJ, Ra C, Yamamoto K: Regulation of mouse mast cell surface FcεRI expression by dexamethasone. Int Immunol 2001;13:843–851.
35.
Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ: Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999;341:1966–1973.
36.
Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, Byrne A, Champain K, Thirlwell J, Cioppa GD, Sandstrom T: Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106:253–259.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.